Nicholas DeVito, Assistant Professor of Medicine at the Division of Medical Oncology at Duke University, shared a post on LinkedIn:
“My lab at Duke Cancer Institute is dedicated to understanding immune evasion during metastasis in colorectal cancer (CRC) and the development of biomarker-selected immunotherapies. We utilize novel immunotherapeutics in advanced orthotopic mouse models, human organoids, and early phase clinical trials to achieve these goals – creating a positive, focused feedback loop centered on radically transforming the first- line standard of care in CRC using our immune system.
Learn more at our website to see our recent progress and a vision of how together, we can (and will) overcome this disease with rational implementation of immunotherapies.”
Other articles featuring Nicholas DeVito.